Leaf, Extract, and Semisynthetic 7-OH Are Not the Same Product — and the Policy Difference Is Everything

Why it matters

Federal regulators, forensic toxicologists, CDC surveillance data, and primary forensic source records all point to the same critical distinction: natural kratom leaf, concentrated extracts, and semisynthetic 7-hydroxymitragynine are pharmacologically and legally different products — but legislation routinely collapses them into one.

The big picture

The most consequential scientific distinction in the kratom policy debate is being systematically ignored in legislation. Every major primary source — from FDA enforcement records to NMS Labs forensic analysis to CDC product-form caveats — draws a line between natural leaf and semisynthetic 7-OH. Prohibition campaigns cross that line as a matter of strategy, not science.

Key findings

• Natural leaf mitragynine: partial mu-opioid agonist, ceiling effect on euphoria and respiratory depression, centuries of traditional use record.
• 7-hydroxymitragynine (7-OH): a metabolite of mitragynine, but concentrated 7-OH products are produced through chemical synthesis at potencies far exceeding natural leaf; classified by NMS as 'not kratom in the ordinary leaf sense.'
• Mitragynine pseudoindoxyl: a further chemical modification; not found in natural leaf.
• FDA July 2025 action: specifically targeted concentrated 7-OH derivative products — FDA Commissioner explicitly stated natural kratom is not the target of federal enforcement.
• 2025 poison-control spike: CDC attributes to semisynthetic 7-OH market expansion, not natural leaf.
• Forensic implication: basic immunoassay panels do not detect 7-OH or pseudoindoxyl; a 'positive for mitragynine' test cannot confirm product form.
• Legislative implication: a prohibition built on 7-OH risk data applied to natural leaf criminalizes a different product than the one creating documented harm.
• CDC limitation: NPDS data cannot distinguish natural leaf from semisynthetic products — making it an unreliable basis for product-specific prohibition.

What they say

"Kratom should not be lumped into bans aimed at those more potent compounds." — Justin Brower, NMS Labs, cited by Open Truth Project

Bottom line

Separating these product categories is not an industry talking point. It is the position of the FDA, CDC, NMS Labs, and the peer-reviewed pharmacology literature. Legislation that fails to make the distinction is not targeting the risk — it is targeting a different product.